Kelun Botai passed the hearing: an annual loss of 600 million and a valuation of 10 billion. Merck and IDG are shareholders
NoSuchKey
Guess you like
Origin blog.csdn.net/leijianping_ce/article/details/131039823
Recommended
Ranking